Mode
Text Size
Log in / Sign up
Phase 3 Completed N=1,044 Treatment

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Source: ClinicalTrials.gov NCT02565914 ↗
Enrolled (actual)
1,044
Serious AEs
31.1%
Results posted
Jun 2020
Primary outcomePrimary: Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 995; 351 Participants
◆ Published Evidence
Established
51citations · ~10 / year
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
The Lancet. Respiratory medicine · 2021 · Open access · Likely link

Summary

This is a Phase 3, multicenter, open-label, 3-part rollover study in subjects with CF who are homozygous or heterozygous for the F508del-CFTR mutation and who participated in studies VX13-661-103 (Study 103, NCT02070744), VX14-661-106 (Study 106, NCT02347657), VX14-661-107 (Study 107, NCT02516410), VX14-661-108 (Study 108, NCT02392234), VX14-661-109 (Study 109, NCT02412111), VX14-661-111 (Study 111, NCT02508207), VX15-661-112 (NCT02730208), and VX16-661-114 (NCT03150719). The study is designed to evaluate the safety and efficacy of long-term treatment of VX-661 in combination with ivacaftor.

Linked Publications

  • Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
    The Lancet. Respiratory medicine · 2021 · 51 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
995; 351
PRIMARY
Part B: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs
427; 136
PRIMARY
Part C: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
168; 44
SECONDARY
Part A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 106/110 Efficacy Set
2.1; 2.0
SECONDARY
Part A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 108/110 Efficacy Set
4.1; 6.7; 7.5
SECONDARY
Part A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/110 Efficacy Set
2.7
SECONDARY
Part A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 111/110 Efficacy Set
4.1; 2.6
SECONDARY
Part A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 106/110 Efficacy Set
4.3; 4.2
SECONDARY
Part A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 108/110 Efficacy Set
7.9; 11.6; 13.0
SECONDARY
Part A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/110 Efficacy Set
6.4
SECONDARY
Part A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 111/110 Efficacy Set
6.1; 5.2
SECONDARY
Part A: Number of Pulmonary Exacerbation (PEx) Events for 106/110 PEx Analysis Set
306; 423
SECONDARY
Part A: Number of Pulmonary Exacerbation (PEx) Events for 108/110 PEx Analysis Set
89; 51; 46
SECONDARY
Part A: Absolute Change in Body Mass Index (BMI) for 106/110 Efficacy Set
0.47; 0.38
SECONDARY
Part A: Absolute Change in Body Mass Index (BMI) for 108/110 Efficacy Set
1.07; 0.96; 1.05
SECONDARY
Part A: Absolute Change in Body Mass Index (BMI) for 103/110 Efficacy Set
1.38
SECONDARY
Part A: Absolute Change in Body Mass Index (BMI) for Study 111/110 Efficacy Set
1.59; 0.26
SECONDARY
Part A: Absolute Change in BMI Z-score for 106/110 Efficacy Set
0.10; -0.14
SECONDARY
Part A: Absolute Change in BMI Z-score for 108/110 Efficacy Set
0.11; 0.07; 0.30
SECONDARY
Part A: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 106/110 Efficacy Set
1.7; 3.0
SECONDARY
Part A: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 108/110 Efficacy Set
10.3; 11.2; 13.8
SECONDARY
Part A: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 103/110 Efficacy Set
8.6
SECONDARY
Part A: Absolute Change in Body Weight for Study 106/110 Efficacy Set
2.0; 2.1
SECONDARY
Part A: Absolute Change in Body Weight for 108/110 Efficacy Set
3.5; 3.5; 3.6
SECONDARY
Part A: Absolute Change in Body Weight for 103/110 Efficacy Set
4.0
SECONDARY
Part A: Absolute Change in Body Weight for 111/110 Efficacy Set
4.2; 0.6
SECONDARY
Part A: Absolute Change in Body Weight Z-score for 106/110 Efficacy Set
0.07; -0.06
SECONDARY
Part A: Absolute Change in Body Weight Z-score for 108/110 Efficacy Set
0.15; 0.09; 0.43
SECONDARY
Part A: Absolute Change in Height Z-score for 106/110 Efficacy Set
0.01; 0.13
SECONDARY
Part A: Absolute Change in Height Z-score for 108/110 Efficacy Set
-0.04; 0.20; 0.23
SECONDARY
Part A: Time-to-first Pulmonary Exacerbation (PEx) for 106/110 PEx Analysis Set
0.470; 0.438
SECONDARY
Part A: Time-to-first Pulmonary Exacerbation (PEx) for 108/110 PEx Analysis Set
0.497; 0.493; 0.639
SECONDARY
Part A: Plasma Concentrations of TEZ, TEZ Metabolite (M1-TEZ), Ivacaftor (IVA) and Ivacaftor Metabolite (M1-IVA)
2070; 4580; 892; 1740
SECONDARY
Part B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
1.7; 8.3
SECONDARY
Part B: Absolute Change in Body Mass Index (BMI)
0.70; 1.84
SECONDARY
Part B: Absolute Change in BMI Z-score
-0.03; 0.21
SECONDARY
Part B: Number of Pulmonary Exacerbation (PEx) Events
386; 94

Eligibility Criteria

Inclusion Criteria

Part A:

  • Participants entering the Treatment Cohort must meet all of the following criteria:
  • Elect to enroll in the Treatment Cohort
  • Completed study drug Treatment Period in a parent study (NCT02070744, NCT02347657, NCT02516410, NCT02392234, NCT02412111) or study drug treatment and the Safety Follow up Visit for participants from NCT02508207.
  • Willing to remain on a stable CF regimen through the Safety Follow-up Visit.
  • Participants re-enrolling in the Part A Treatment Cohort must meet all of the following criteria:
  • Previously received at least 4 weeks of study drug before discontinuing in Part A of Study NCT02565914 to participate in another qualified Vertex study.
  • Completed the last required visit of another qualified Vertex study before or during the Returning Visit in Part A Study NCT02565914.
  • Participants entering the Part A Observational Cohort must meet the following criteria:
  • <18 years of age (age on the date of informed consent/assent in the parent study)
  • Completed study drug Treatment Period in a parent study or study drug treatment and the Safety Follow up Visit for subjects from NCT02508207, but do not elect to enroll in the NCT02565914 Treatment Cohort; or
  • Received at least 4 weeks of study drug treatment and completed visits up to the last scheduled visit of the Treatment Period of a parent study (and the Safety Follow up Visit for participants from NCT02508207), but do not meet eligibility criteria for enrollment into the Treatment Cohort

Part B:

Participants who meet all of the following inclusion criteria will be eligible for Part B.

  • Did not withdraw consent from the parent study or Part A of Study NCT02565914.
  • Completed study drug treatment during the Treatment Period in Part A of - Willing to remain on a stable CF medication (and supplement) regimen through the 96 week visit of Study NCT02565914.

Participants re enrolling in Part B must meet all of the following criteria:

  • Previously received at least 4 weeks of study drug before discontinuing Study NCT02565914 to participate in another qualified Vertex study, which is defined as a Vertex study of investigational CFTR modulators that allows participation of participants in Study NCT02565914.
  • Completed the last required visit of another qualified Vertex study before or during the Returning Visit in Part B.
  • Willing to remain on a stable CF medication (and supplement) regimen through the 96 week visit in Part B.

Part C:

  • Participants who meet all of the following inclusion criteria will be eligible for Part C.
  • Did not withdraw consent from Part B of Study NCT02565914.
  • Completed study drug treatment during Part B of NCT02565914.
  • Willing to remain on a stable CF medication (and supplement) regimen through the 96 week visit of Part C.

Exclusion Criteria

  • History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the subject.
  • Pregnant and nursing females.
  • Sexually active subjects of reproductive potential who are not willing to follow the contraception requirements.
  • History of drug intolerance in the parent study that would pose an additional risk to the subject.
  • Participation in an investigational drug trial (including studies investigating VX-661/ivacaftor or lumacaftor/ivacaftor) other than the parent studies of NCT02565914 or other eligible Vertex studies investigating VX-661 in combination with ivacaftor, or use of a commercially available CFTR modulator.

Other protocol defined Inclusion/Exclusion criteria may apply.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02565914) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search